KRTX News and Press, Karuna Therapeutics Inc. From 08/08/22

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and nega...

During the second quarter of 2022, the Miller Opportunity Trust – Class I shares generated a total return of -29.45% excluding sales charges. Using a three-factor performance attribution model, selection, allocation and interaction effects contributed to the portfolio’s ...

Clinical-stage biotech Karuna Therapeutics ( NASDAQ: KRTX ) reversed a sharp decline on Friday after a director of the company disclosed an insider purchase of company shares worth more than $14M. According to the regulatory filing, Healy James, a General Partner of So...

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event. Despite cash balance issues and new clinical stage competitors, market  indica...

Webcast scheduled for Wednesday, May 25, 2022, at 8:00 a.m. ET Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today ann...

Karuna Therapeutics press release (NASDAQ:KRTX): Q1 GAAP EPS of -$1.95 beats by $0.19. Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in the third quarter of 2022 and in the first quarter of 2023. The company is on track to initiate Phase 3 program evaluating KarXT fo...

Completed enrollment in the Phase 3 EMERGENT-2 trial evaluating KarXT for the treatment of schizophrenia in the second quarter of 2022 Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in the third quarter of 2022 and in the first quarter of 2023, respect...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer, will...

100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...

As the Russian invasion of Ukraine continues, several pharma and biotech companies have exposure to both countries through clinical trials being conducted there. One biotech, Karuna Therapeutics (NASDAQ:KRTX), has already said the disturbance has impacted a late-stage trial. On Thursday, the ...